Sandoz Group AG

Read how Sandoz’s $350 M acquisition of Just‑Evotec Biologics boosts its continuous‑manufacturing biosimilar capacity, cutting costs and speeding market launch for affordable biologics.

Sandoz Group AG has announced several key developments, including the launch of a generic rivaroxaban treatment in Germany and a CAD 220 million investment in its Boucherville plant.

Sandoz Group AG reports strong financial results for the first half of 2025, driven by 12% growth in biosimilars sales and a 20.0% core EBITDA margin.

Sandoz Group AG’s stock price has risen due to its focus on generic and biosimilar medicines, but the company faces a challenge from Biocon’s plans to file for regulatory approvals of generic versions of popular diabetes medications.

Sandoz Group AG solidifies its biosimilars leadership with a significant investment in a new facility in Slovenia, positioning the company for growth in the burgeoning biosimilar market.

Sandoz Group AG is poised to capitalize on the growing demand for affordable treatment options, with the global biosimilars market expected to reach a valuation of over $72 billion by 2035.

Sandoz Group AG has launched two interchangeable denosumab biosimilars, WYOST and Jubbonti, in the US market, expanding treatment options for millions of patients with osteoporosis and cancer-related skeletal events.

Sandoz has reported Q1 2025 net sales in line with expectations, but its financial ratios, including a price-to-earnings ratio of -24,640, indicate significant deviation from industry norms.

Sandoz Group AG reported strong FY 2024 results, driven by double-digit growth in its biosimilars segment, and expects continued growth in 2025 with mid-single digit net-sales growth and improved profitability.